Perceptive Advisors
NEW YORK, NYfiles as PERCEPTIVE ADVISORS LLC
$6.4bn in 101 US stocks at the end of 30 June 2026. The top 10 are 49.0% of the money. It changed about 26.4% of the portfolio this quarter.
Value
$6.4bn
Stocks
101
Top 10 share
49.0%
Turnover
26.4%
What changed this quarter
New
Bought for the first time this quarter.
- Ascendis Pharma A/SASND4.8% of the fund
- KardiganKARD3.0% of the fund
- Avalyn PharmaAVLN1.4% of the fund
- BiogenBIIB0.9% of the fund
- UnitedHealth GroupUNH0.8% of the fund
- Charles River Laboratories InternationalCRL0.5% of the fund
- DanaherDHR0.4% of the fund
- Adlai NortyeANL0.3% of the fund
- Nuvectis PharmaNVCT0.3% of the fund
- Mirum PharmaceuticalsMIRM0.2% of the fund
- Oscar HealthOSCR0.2% of the fund
- Seaport TherapeuticsSPTX0.2% of the fund
- Boston ScientificBSX0.2% of the fund
- NateraNTRA0.1% of the fund
- enGene TherapeuticsENGN0.1% of the fund
- Research Alliance Corp IIIRACC0.1% of the fund
- Cullinan TherapeuticsCGEM0.1% of the fund
- uniQureQURE0.1% of the fund
- Mobia MedicalMOBI0.1% of the fund
- Outlook TherapeuticsOTLK<0.1% of the fund
- Xeris Biopharma HoldingsXERS<0.1% of the fund
- BiodesixBDSX<0.1% of the fund
- Kiora PharmaceuticalsKPRX<0.1% of the fund
Added
Bought more of a stock they already held.
- Spyre TherapeuticsSYRE6.0% of the fund+14%
- CelcuityCELC5.2% of the fund+2%
- Rhythm PharmaceuticalsRYTM4.5% of the fund+9%
- Relay TherapeuticsRLAY4.1% of the fund+45%
- MeiraGTx HoldingsMGTX2.3% of the fund+4%
- ZymeworksZYME1.7% of the fund+19%
- Tango TherapeuticsTNGX1.6% of the fund+318%
- Nurix TherapeuticsNRIX1.6% of the fund+16%
- Biocryst PharmaceuticalsBCRX1.6% of the fund+39%
- Revolution MedicinesRVMD1.5% of the fund+104%
- Ionis PharmaceuticalsIONS0.7% of the fund+12%
- Sutro BiopharmaSTRO0.7% of the fund+82%
- Corvus PharmaceuticalsCRVS0.6% of the fund+16%
- Sionna TherapeuticsSION0.6% of the fund+37%
- CytomX TherapeuticsCTMX0.6% of the fund+3%
- ArtivionAORT0.6% of the fund+6%
- X4 PharmaceuticalsXFOR0.6% of the fund+18%
- Corcept TherapeuticsCORT0.5% of the fund+697%
- Rapport TherapeuticsRAPP0.5% of the fund+15%
- DBV Technologies S ADBVT0.4% of the fund+71%
- iRhythm HoldingsIRTC0.4% of the fund+113%
- Adaptive BiotechnologiesADPT0.4% of the fund+698%
- SAB BiotherapeuticsSABS0.4% of the fund+3%
- Tenax TherapeuticsTENX0.4% of the fund+17%
- EvolusEOLS0.3% of the fund+91%
Cut
Sold some of their stake.
- Roivant SciencesROIV4.5% of the fund-2%
- Travere TherapeuticsTVTX3.3% of the fund-9%
- Apogee TherapeuticsAPGE2.7% of the fund-15%
- Oruka TherapeuticsORKA2.0% of the fund-4%
- Inhibrx BiosciencesINBX1.9% of the fund-10%
- Protagonist TherapeuticsPTGX1.9% of the fund-20%
- Dyne TherapeuticsDYN0.9% of the fund-42%
- ImmunovantIMVT0.8% of the fund-15%
- Alto NeuroscienceANRO0.7% of the fund-20%
- RepligenRGEN0.5% of the fund-12%
- Axsome TherapeuticsAXSM0.5% of the fund-21%
- Nautilus BiotechnologyNAUT0.3% of the fund-8%
- Intuitive SurgicalISRG0.3% of the fund-39%
- Palisade BIOPALI0.3% of the fund-6%
- InvivydIVVD0.3% of the fund-11%
- AxogenAXGN0.2% of the fund-65%
- Viridian TherapeuticsVRDN0.2% of the fund-50%
- BillionToOneBLLN0.2% of the fund-5%
- Abivax SAABVX0.2% of the fund-78%
- Guardant HealthGH<0.1% of the fund-86%
- Phathom PharmaceuticalsPHAT<0.1% of the fund-42%
- Twist BioscienceTWST<0.1% of the fund-75%
- Adma BiologicsADMA<0.1% of the fund-76%
- Cumberland PharmaceuticalsCPIX<0.1% of the fund-51%
Sold out
Sold their entire stake.
- Ascendis Pharma A/SASND-100%
- Centessa Pharmaceuticals-100%
- Engene Holdings-100%
- DAY One Biopharmaceuticals I-100%
- Bright Minds BiosciencesDRUG-100%
- Belite BIOBLTE-100%
- EvommuneEVMN-100%
- Neumora TherapeuticsNMRA-100%
- Neurocrine BiosciencesNBIX-100%
- Opus GeneticsIRD-100%
- Inhibikase TherapeuticsIKT-100%
- Apellis Pharmaceuticals-100%
- Palatin TechnologiesPTN-100%
Holdings
- KardiganKARD
- Share
- 3.0%
- Value
- $196m
- Shares
- 8,200,662
New
- Nuvalent
- Share
- 3.0%
- Value
- $195m
- Shares
- 1,580,505
Held
- Apogee TherapeuticsAPGE
- Share
- 2.7%
- Value
- $174m
- Shares
- 1,308,113
-15%
- Avalyn PharmaAVLN
- Share
- 1.4%
- Value
- $88m
- Shares
- 2,675,296
New
- Damora Therapeutics
- Share
- 0.5%
- Value
- $32m
- Shares
- 1,223,000
Held
- DBV Technologies S ADBVT
- Share
- 0.4%
- Value
- $27m
- Shares
- 1,653,350
+71%
- Adlai NortyeANL
- Share
- 0.3%
- Value
- $21m
- Shares
- 1,793,190
New
- Seaport TherapeuticsSPTX
- Share
- 0.2%
- Value
- $11m
- Shares
- 500,000
New
- Abivax SAABVX
- Share
- 0.2%
- Value
- $10m
- Shares
- 74,000
-78%
- Research Alliance Corp IIIRACC
- Share
- 0.1%
- Value
- $8m
- Shares
- 750,000
New
- Mobia MedicalMOBI
- Share
- 0.1%
- Value
- $7m
- Shares
- 523,654
New
- Revolution MedicinesRVMDW
- Share
- <0.1%
- Value
- $2m
- Shares
- 250,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Praxis Precision MedicinesPRAX | 10.6% | $682m | 2,035,986 | Held |
| Spyre TherapeuticsSYRE | 6.0% | $383m | 4,319,496 | +14% |
| CelcuityCELC | 5.2% | $334m | 3,197,200 | +2% |
| Ascendis Pharma A/SASND | 4.8% | $310m | 1,163,721 | New |
| Rhythm PharmaceuticalsRYTM | 4.5% | $287m | 2,586,295 | +9% |
| Roivant SciencesROIV | 4.5% | $286m | 8,085,461 | -2% |
| Relay TherapeuticsRLAY | 4.1% | $264m | 14,106,187 | +45% |
| Travere TherapeuticsTVTX | 3.3% | $213m | 3,752,574 | -9% |
| KardiganKARD | 3.0% | $196m | 8,200,662 | New |
| Nuvalent | 3.0% | $195m | 1,580,505 | Held |
| Edgewise TherapeuticsEWTX | 2.8% | $178m | 4,373,974 | Held |
| Apogee TherapeuticsAPGE | 2.7% | $174m | 1,308,113 | -15% |
| Amylyx PharmaceuticalsAMLX | 2.3% | $150m | 8,334,882 | Held |
| MeiraGTx HoldingsMGTX | 2.3% | $146m | 10,786,658 | +4% |
| Oruka TherapeuticsORKA | 2.0% | $128m | 1,345,063 | -4% |
| Inhibrx BiosciencesINBX | 1.9% | $123m | 1,297,763 | -10% |
| Protagonist TherapeuticsPTGX | 1.9% | $120m | 981,879 | -20% |
| Solid BiosciencesSLDB | 1.9% | $119m | 11,906,646 | Held |
| ZymeworksZYME | 1.7% | $109m | 4,182,953 | +19% |
| Tango TherapeuticsTNGX | 1.6% | $106m | 3,377,000 | +318% |
| ImmaticsIMTX | 1.6% | $105m | 10,383,456 | Held |
| Nurix TherapeuticsNRIX | 1.6% | $105m | 4,320,422 | +16% |
| Biocryst PharmaceuticalsBCRX | 1.6% | $103m | 10,308,888 | +39% |
| Revolution MedicinesRVMD | 1.5% | $99m | 527,600 | +104% |
| Avalyn PharmaAVLN | 1.4% | $88m | 2,675,296 | New |
| Dyne TherapeuticsDYN | 0.9% | $60m | 2,689,235 | -42% |
| BiogenBIIB | 0.9% | $60m | 276,173 | New |
| ImmunovantIMVT | 0.8% | $52m | 1,357,383 | -15% |
| UnitedHealth GroupUNH | 0.8% | $49m | 116,806 | New |
| Ionis PharmaceuticalsIONS | 0.7% | $45m | 566,000 | +12% |
| Sutro BiopharmaSTRO | 0.7% | $43m | 1,304,846 | +82% |
| Alto NeuroscienceANRO | 0.7% | $42m | 1,609,893 | -20% |
| Jazz PharmaceuticalsJAZZ | 0.6% | $41m | 170,000 | Held |
| Corvus PharmaceuticalsCRVS | 0.6% | $40m | 2,667,441 | +16% |
| Sionna TherapeuticsSION | 0.6% | $40m | 905,000 | +37% |
| CytomX TherapeuticsCTMX | 0.6% | $39m | 10,439,185 | +3% |
| ArtivionAORT | 0.6% | $39m | 1,737,290 | +6% |
| X4 PharmaceuticalsXFOR | 0.6% | $37m | 7,933,491 | +18% |
| Corcept TherapeuticsCORT | 0.5% | $35m | 398,385 | +697% |
| RepligenRGEN | 0.5% | $34m | 248,212 | -12% |
| Anteris Technologies GlobalAVR | 0.5% | $34m | 3,425,476 | Held |
| Rapport TherapeuticsRAPP | 0.5% | $32m | 773,342 | +15% |
| Damora Therapeutics | 0.5% | $32m | 1,223,000 | Held |
| Charles River Laboratories InternationalCRL | 0.5% | $32m | 140,000 | New |
| Axsome TherapeuticsAXSM | 0.5% | $29m | 118,450 | -21% |
| DBV Technologies S ADBVT | 0.4% | $27m | 1,653,350 | +71% |
| iRhythm HoldingsIRTC | 0.4% | $27m | 223,766 | +113% |
| Adaptive BiotechnologiesADPT | 0.4% | $26m | 1,217,325 | +698% |
| SAB BiotherapeuticsSABS | 0.4% | $26m | 6,627,501 | +3% |
| DanaherDHR | 0.4% | $25m | 130,000 | New |
| Tenax TherapeuticsTENX | 0.4% | $25m | 1,700,000 | +17% |
| Nautilus BiotechnologyNAUT | 0.3% | $22m | 11,634,211 | -8% |
| Orchestra BioMed HoldingsOBIO | 0.3% | $22m | 5,037,906 | Held |
| Intuitive SurgicalISRG | 0.3% | $21m | 51,884 | -39% |
| Adlai NortyeANL | 0.3% | $21m | 1,793,190 | New |
| Contineum TherapeuticsCTNM | 0.3% | $21m | 1,255,592 | Held |
| Nuvectis PharmaNVCT | 0.3% | $18m | 1,000,000 | New |
| Palisade BIOPALI | 0.3% | $18m | 8,425,065 | -6% |
| Omada HealthOMDA | 0.3% | $17m | 786,330 | Held |
| LeonaBioLONA | 0.3% | $17m | 1,859,322 | Held |
| EvolusEOLS | 0.3% | $17m | 2,459,285 | +91% |
| InvivydIVVD | 0.3% | $16m | 18,490,636 | -11% |
| Mirum PharmaceuticalsMIRM | 0.2% | $14m | 115,391 | New |
| SurrozenSRZN | 0.2% | $13m | 503,985 | +120% |
| Beta BionicsBBNX | 0.2% | $13m | 832,944 | Held |
| AxogenAXGN | 0.2% | $11m | 247,312 | -65% |
| Oscar HealthOSCR | 0.2% | $11m | 400,000 | New |
| Oculis Holding AGOCS | 0.2% | $11m | 808,827 | +64% |
| Seaport TherapeuticsSPTX | 0.2% | $11m | 500,000 | New |
| Viridian TherapeuticsVRDN | 0.2% | $11m | 581,980 | -50% |
| Boston ScientificBSX | 0.2% | $11m | 250,000 | New |
| BillionToOneBLLN | 0.2% | $10m | 86,812 | -5% |
| Abivax SAABVX | 0.2% | $10m | 74,000 | -78% |
| NateraNTRA | 0.1% | $9m | 34,689 | New |
| enGene TherapeuticsENGN | 0.1% | $8m | 4,822,169 | New |
| Research Alliance Corp IIIRACC | 0.1% | $8m | 750,000 | New |
| AgomAb Therapeutics NVAGMB | 0.1% | $8m | 600,000 | Held |
| Cullinan TherapeuticsCGEM | 0.1% | $8m | 426,478 | New |
| uniQureQURE | 0.1% | $8m | 168,000 | New |
| Mobia MedicalMOBI | 0.1% | $7m | 523,654 | New |
| Adagio Medical HoldingsADGM | 0.1% | $6m | 9,876,586 | Held |
| Guardant HealthGH | <0.1% | $6m | 41,327 | -86% |
| Phathom PharmaceuticalsPHAT | <0.1% | $6m | 532,000 | -42% |
| Outlook TherapeuticsOTLK | <0.1% | $5m | 3,139,216 | New |
| Cogent BiosciencesCOGT | <0.1% | $5m | 121,082 | Held |
| Edesa BiotechEDSA | <0.1% | $5m | 563,239 | Held |
| Avalo TherapeuticsAVTX | <0.1% | $4m | 219,813 | +57% |
| Twist BioscienceTWST | <0.1% | $4m | 36,812 | -75% |
| Crescent BiopharmaCBIO | <0.1% | $4m | 206,942 | Held |
| Xeris Biopharma HoldingsXERS | <0.1% | $4m | 467,013 | New |
| Outset MedicalOM | <0.1% | $4m | 833,333 | Held |
| BiodesixBDSX | <0.1% | $2m | 108,694 | New |
| Revolution MedicinesRVMDW | <0.1% | $2m | 250,000 | Held |
| Connect Biopharma HoldingsCNTB | <0.1% | $2m | 792,696 | Held |
| Kiora PharmaceuticalsKPRX | <0.1% | $1m | 438,471 | New |
| MedlineMDLN | <0.1% | $1m | 28,000 | Held |
| Adma BiologicsADMA | <0.1% | $952,213 | 113,765 | -76% |
| Cumberland PharmaceuticalsCPIX | <0.1% | $628,443 | 96,982 | -51% |
| ExagenXGN | <0.1% | $534,252 | 114,893 | Held |
| Ensysce BiosciencesENSC | <0.1% | $25,133 | 86,666 | Held |
Showing the largest 100 of 101.
Options (7)
- ModernaMRNA
- Type
- Put
- Value
- $70m
- Contracts
- 1,000,000
- Spdr Series TrustXBI
- Type
- Put
- Value
- $47m
- Contracts
- 300,000
- EyePointEYPT
- Type
- Put
- Value
- $29m
- Contracts
- 2,000,000
- Capricor TherapeuticsCAPR
- Type
- Call
- Value
- $24m
- Contracts
- 1,000,000
- SELLAS Life Sciences GroupSLS
- Type
- Put
- Value
- $22m
- Contracts
- 1,500,000
- NewAmsterdam PharmaNAMS
- Type
- Put
- Value
- $17m
- Contracts
- 500,000
- Capricor TherapeuticsCAPR
- Type
- Put
- Value
- $12m
- Contracts
- 500,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| ModernaMRNA | Put | $70m | 1,000,000 |
| Spdr Series TrustXBI | Put | $47m | 300,000 |
| EyePointEYPT | Put | $29m | 2,000,000 |
| Capricor TherapeuticsCAPR | Call | $24m | 1,000,000 |
| SELLAS Life Sciences GroupSLS | Put | $22m | 1,500,000 |
| NewAmsterdam PharmaNAMS | Put | $17m | 500,000 |
| Capricor TherapeuticsCAPR | Put | $12m | 500,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 141.1% since 30 June 2025.
Where the money is
Health care95.4%
Financial services0.2%
Other4.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.